SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial
results for the fourth quarter and year-ended December 31, 2020, on Thursday, February 25,
2021, after the close of U.S.-based financial
markets. Howard Robin, President and Chief Executive Officer,
will host a conference call to review the results beginning
at 5:00 p.m. Eastern Time/2:00 p.m.
Pacific Time.
The press release and live audio-only webcast of the conference
call can be accessed through a link that is posted on the Home Page
and Investors section of the Nektar
website: http://ir.nektar.com/. The web broadcast of the
conference call will be available for replay through Thursday,
March 25, 2021.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453
(international)
Conference ID: 3857247 (Nektar Therapeutics is the
host)
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a
robust, wholly owned R&D pipeline of investigational medicines
in oncology, immunology, and virology as well as a portfolio of
approved partnered medicines. Nektar is headquartered in San
Francisco, California, with
additional operations in Huntsville,
Alabama and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found
online at http://www.nektar.com.
Contacts:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2020-on-thursday-february-25-2021-after-close-of-us-based-financial-markets-301231344.html
SOURCE Nektar Therapeutics